Document:

EX-10.7.1

 Exhibit 10.7.1 

THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT 

This Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 31st day of October, 2013, by and
among (a) SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara. California 95054 and with a loan production office located at 3005 Carrington Mill Boulevard, Suite 530,
Morrisville, North Carolina 27560 (“SVB”), as collateral agent (in such capacity, the “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto
from time to time including SVB in its capacity as a Lender, and OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Finance”), OXFORD
FINANCE FUNDING I, LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Funding”), and OXFORD FINANCE FUNDING TRUST 2012-01, a Delaware trust with an
office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Trust”; and together with Finance and Funding, collectively “Oxford”) (SVB and Oxford are each a “Lender” and collectively,
the “Lenders”), and (b) (i) TRANSENTERIX, INC., a Delaware corporation, with its principal place of business at 635 Davis Drive, Suite 300, Morrisville, North Carolina 27560 (“TransEnterix”),
(ii) SAFESTITCH MEDICAL, INC., a Delaware corporation, with its chief executive office located at 4400 Biscayne Boulevard, Suite 570, Miami, Florida 33137 (“SafeStitch”), and (iii) SAFESTITCH LLC, a Virginia
limited liability company, with its chief executive office located at 4400 Biscayne Boulevard, Suite 570, Miami, Florida 33137 (“SafeStitch LLC”) (TransEnterix, SafeStitch, and SafeStitch LLC are hereinafter jointly and severally,
individually and collectively, referred to as “Borrower”). 
 RECITALS 

A. Lenders and Borrower entered into that certain Loan and Security Agreement dated as of January 17, 2012, between Existing Borrower and
Lenders, as amended by a certain First Amendment to Loan and Security Agreement dated as of February 11, 2013, and as further amended by a certain Second Amendment to Loan and Security Agreement and Joinder Agreement dated September 3,
2013 (as may be further amended modified, supplemented or restated from time to time, the “Loan Agreement”). All capitalized terms used herein without definitions shall have the meanings given such terms in the Loan Agreement. 

B. Lenders have extended credit to Borrower for the purposes permitted in the Loan Agreement. 

C. Borrower has requested that Lender amend the Loan Agreement, as fully set forth herein. 

D. Lenders have agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to
the conditions and in reliance upon the representations and warranties set forth below. 
 AGREEMENT 

NOW, THEREORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is
hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: 
 1. Definitions. All capitalized terms used herein
without definitions shall have the meanings given such terms in the Loan Agreement. 

 2. Amendments to the Loan Agreement. 

 

	 	A.	Section 6.2 (Financial Statements, Reports, Certificates, Inspections). The Loan Agreement shall be amended by (a) deleting the “and” at the end of clause (viii) thereof, (b) deleting the
at the end of (ix) thereof and replacing it with and” and (c) inserting the following new provision to appear as 6.2(a)(x) thereof: 

“ (x) as soon as available, but no later than thirty (30) days after the last day of each month, a copy of Borrower’s monthly
rental check payable to the landlord of Borrower’s leased location at 627 Distribution Drive, Durham, North Carolina 27560.” 
  

	 	B.	Exhibit C (Compliance Certificate). The Compliance Certificate is amended in its entirety and replaced with the Compliance Certificate in the form of Schedule 1 attached hereto. 

3. Limitation of Amendments. 
 3.1 The
amendments set forth in Section 2 above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or
condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Lenders may now have or may have in the future under or in connection with any Loan Document. 

3.2 This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations,
warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect. 

4. Representations and Warranties. To induce Lenders to enter into this Amendment, Borrower hereby represents and warrants to Lenders as follows: 

4.1 Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true,
accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has
occurred and is continuing; 
 4.2 Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations
under the Loan Agreement, as amended by this Amendment; 
 4.3 The organizational documents of Borrower delivered to Lenders on the
Effective Date remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect; 

4.4 The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as
amended by this Amendment, have been duly authorized; 
 4.5 The execution and delivery by Borrower of this Amendment and the performance by
Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on
Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower; 

4.6 The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as
amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding
on either Borrower, except as already has been obtained or made; and 

 4.7 This Amendment has been duly executed and delivered by Borrower and is the binding obligation
of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable
principles relating to or affecting creditors’ rights. 
 5. Integration. This Amendment and the Loan Documents represent the entire agreement
about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge
into this Amendment and the Loan Documents. 
 6. Counterparts. This Amendment may be executed in any number of counterparts and all of such
counterparts taken together shall be deemed to constitute one and the same instrument. 
 7. Effectiveness. This Amendment shall be deemed effective
upon (a) the due execution and delivery to Lenders of this Amendment by each party hereto, and (b) Borrower’s payment of Lenders’ legal fees and expenses incurred in connection with this Amendment. 

[Signature pages follow] 

 IN WITNESS WHEREOF, this Amendment is being executed as of the date first written above. 

 

			
	BORROWER:
	
	SAFESTITCH MEDICAL, INC.
		
	By:	 	

	Name:	 	 Todd M Pope

	Title:	 	 CEO

	
	SAFESTITCH LLC
		
	By:	 	

	Name:	 	 Todd M Pope

	Title:	 	 CEO

	
	TRANSENTERIX, INC.
		
	By	 	

	Name:	 	 Todd M Pope

	Title:	 	 CEO

	
	COLLATERAL AGENT AND LENDER:
	
	SILICON VALLEY BANK
		
	By:	 	

		
	Name:	 	 Patrick Q. Scheper

		
	Title:	 	 Vice President

	
	LENDER:
	
	OXFORD FINANCE FUNDING I, LLC
	By:	 	Oxford Finance LLC, as servicer
		
	By:	 	

		
	Name:	 	 Mark Davis

		
	Title:	 	 Vice President - Finance, Secretary & Treasurer

	
	OXFORD FINANCE FUNDING TRUST 2012-01
	By:	 	Oxford Finance LLC, as servicer
		
	By:	 	

		
	Name:	 	 Mark Davis

		
	Title:	 	 Vice President - Finance, Secretary & Treasurer

 SCHEDULE 1 

EXHIBIT C 

Compliance Certificate 
  

			
	TO:	  	 SILICON VALLEY BANK, as Collateral Agent and Lender

OXFORD FINANCE LLC, as Lender

		
	FROM:	  	 TRANSENTERIX, INC.

SAFESTITCH MEDICAL, INC.

SAFESTITCH LLC

 The undersigned authorized officer (“Officer”) of TRANSENTERIX, INC., SAFESTITCH MEDICAL, INC., and
SAFESTITCH LLC (collectively, the “Borrower”), hereby certifies, solely in his or her capacity as an officer of Borrower and not in any individual capacity, that in accordance with the terms and conditions of the Loan and Security
Agreement by and among Borrower, Collateral Agent, and the Lenders (the “Agreement”), 
 (i) Borrower is in complete compliance for the
period ending                      with all required covenants except as noted below; 

(ii) There are no Events of Default, except as noted below; 

(iii) Except as noted below, all representations and warranties of Borrower stated in the Loan Documents are true and correct in all material respects on this
date except as noted below; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those
representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date. 
 (iv)
Borrower, and each of Borrower’s Subsidiaries, has timely filed all required tax returns and reports, Borrower, and each of Borrower’s Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and
contributions owed by Borrower, or Subsidiary, except as otherwise permitted pursuant to the terms of Section 5.8 of the Agreement; 
 (v) No Liens
have been levied or claims made against Borrower or any of Borrower’s Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Collateral Agent and the Lenders. 

Attached are the required documents, if any, supporting our certification(s). The Officer, on behalf of Borrower, further certifies that the attached
financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in the case of
unaudited financial statements, for the absence of footnotes and subject to year-end audit adjustments as to the interim financial statements. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the
Agreement. 

 Please indicate compliance status since the last Compliance Certificate by circling Yes, No,
or N/A under “Complies” column. 
  

															
	 	  	 Reporting Covenant
	    	 Requirement
	  	 	 	  	Complies
	 1)
	  	Financial statements	    	Monthly within 30 days	  				  	Yes	  	No	  	N/A
							
	 2)
	  	Annual (CPA Audited) statements	    	Within 120 days after Fiscal Year End	  				  	Yes	  	No	  	N/A
							
	 3)
	  	Annual Financial Projections/Budget (prepared on a monthly basis)	    	Annually (w/n 10 days of FYE) and when revised	  				  	Yes	  	No	  	N/A
							
	 4)
	  	A/R & A/P agings	    	If applicable	  				  	Yes	  	No	  	N/A
							
	 5)
	  	8-K, 10-K and 10-Q Filings	    	If applicable	  				  	Yes	  	No	  	N/A
							
	 6)
	  	Compliance Certificate	    	Monthly within 30 days	  				  	Yes	  	No	  	N/A
							
	 7)
	  	Dissolution of ISIS Tele-Communications, Inc.	    	Within 6 months after 2013 Effective Date	  				  	Yes	  	No	  	N/A
							
	 8)
	  	Copy of rental check (627 Distribution Drive)	    	Monthly within 30 days	  				  	Yes	  	No	  	N/A
							
		  	IP Report *	    	Monthly within 30 days	  				  	Yes	  	No	  	N/A
							
	 9)
	  	Total amount of Borrower’s cash and cash equivalents at the last day of the measurement period	    		  	$	            	  	  		  		  	
			
		  	Deposit and Securities Accounts	    	(Please list all accounts; attach separate sheet if additional space needed)
					
	 	  	 Bank
	    	 Account Number
	  	New Account?	  	Acct Control
Agmt in place?
	 1)
	  		    		  	 	Yes	  	  	No	  	Yes	  	No
							
	 2)
	  		    		  	 	Yes	  	  	No	  	Yes	  	No
							
	 3)
	  		    		  	 	Yes	  	  	No	  	Yes	  	No
							
	 4)
	  		    		  	 	Yes	  	  	No	  	Yes	  	No
							
	 5)
	  		    		  	 	Yes	  	  	No	  	Yes	  	No
							
	 6)
	  		    		  	 	Yes	  	  	No	  	Yes	  	No

	
	Bank Services
	
	Amount of cash secured
	Bank Services:
	$        
	
	 Amount of non-cash
 secured Bank
Services

	$        

  

							
	Other Matters	  		  		  	
				
	Have any Key Persons departed or ceased to be employed since the last Compliance Certificate?	  	Yes        	  	No        	  	
				
	Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the Agreement?	  	Yes        	  	No        	  	
				
	Have there been any new or pending claims or causes of action against Borrower that involve more than $150,000?	  	Yes        	  	No        	  	

  

	*	The following Intellectual Property was registered (or a registration application submitted) after the Effective Date or the most recent Compliance Certificate, as applicable (if no registrations, state
“None”) 

  

							
	  
  
	  		  		  	

  

			
	Exceptions	  	
		
	Please explain any exceptions with respect to the certification above: (If no exceptions exist, state “No exceptions.” Attach separate sheet if additional space needed.)	  	  
  

	  	  
  

	  	  
  

	  	  

  

									
		  	  
	  		  	 LENDERS USE

ONLY

	SAFESTITCH MEDICAL, INC., as Administrative Borrower	  	DATE	  		  		  	 
				 	 
	By:	  	  
	  		  		  	 
	Name:	  		  		  		  	 
	Title:	  	  
	  		  		  	 
		  		  		  		  	 
		  	  
	  		  		  	 
	TRANSENTERIX, INC.	  	DATE	  		  		  	 
				 	 
	By:	  		  		  	Received by:                     	  	Verified by:                      
	 Name:
	  		  		  		  	 
	 Title:
	  		  		  	                     	  	    
                

									
	SAFESTITCH	  	DATE	  		  		  	 
	MEDICAL, INC.	  		  		  		  	 
				 	 
	By:	  		  		  		  	 
	Name:	  		  		  		  	 
	Title:	  		  		  		  	 
				 	 
	 SAFESTITCH LLC
	  	DATE	  		  		  	 
				 	 
	By:	  		  		  		  	 
	Name:	  		  		  		  	 
	Title:	  		  		  		  	 
		  		  		  	 Compliance Status
  

 
	  	 Yes
                     NoEX-10.8

 Exhibit 10.8 

Amended and Restated Pre-Release Distribution Agreement 

Preamble: 
 The purpose of this agreement,
effective as of 15 June 2012, is to cover the business arrangement between TransEnterix, Inc. (“MANUFACTURER”) and Al Danah Medical Co. W.L.L. (“DISTRIBUTOR”) (MANUFACTURER and DISTRIBUTOR collectively the
“Parties”) during a limited pre-market-release of the SPIDER Surgical System in a select Territory within Europe. This agreement amends and restates, and supersedes in all respects, the Pre-Release Distribution Agreement entered into
between the Parties as of [insert prior date]. 
 Terms: 

1). Territory – DISTRIBUTOR agrees to only sell TransEnterix products exclusively in the respective territory listed in Annex 1 (the
“Territory”). 
 2). Accounts –DISTRIBUTOR agrees to sell exclusively to mutually and pre-agreed Key Opinion Leading end-user
customers listed in Annex 2. DISTRIBUTOR agrees to include additional end-user customers only with the prior written approval of TransEnterix. 

3). Pricing and Terms – products will be sold to DISTRIBUTOR at transfer pricing in USD, as per price list in Annex 3. Payment terms are
Net 60 days. 
 4). Shipping – products will be shipped FOB at location of origin. Delivery and acceptance of product shall be in
accordance with the Uniform Commercial Code as it is in force in the Country where the shipment originated. 
 5). Single-Use samples –
TransEnterix will provide DISTRIBUTOR with one Demonstration /Training Set of SPIDER single-use products for each KOL End-User customer free of Charge. 

6). Reusable equipment – TransEnterix will loan DISTRIBUTOR one (1) re-usable grasper and one (1) support arm for each KOL
End-User customer for the duration of agreement. 
 7). Marketing Support and Training – TransEnterix will provide DISTRIBUTOR with
marketing support, clinical training, Key Customer Visits, where applicable. DISTRIBUTOR will provide trained clinical staff at all times during SPIDER Surgery procedures with KOL End-user customers. Clinical support representation from TransEnterix
(Robin Hembry, Johan Ceuppens, US clinical training) will have the option to support pre-release cases performed under this agreement, as appropriate. 

8). Product Ordering and Returns – purchase order quantities be approved in advance by TransEnterix, to ensure product availability for
full orders. Product returns of full and unopened boxes will be permitted, so long as the boxes are returned in original condition (utilizing over-shipper boxes). 

 9). Customer Complaints; Inquiries. DISTRIBUTOR hereby covenants that it shall be
responsible as the first point of contact for technical support with the customer and/or end-users. DISTRIBUTOR will provide a line of communication to MANUFACTURER and MANUFACTURER’S AUTHORIZED REPRESENTATIVE (see contact information below)
directly in matters of vigilance and post-market surveillance (early warning) in accordance with the European Commission Guidelines On A Medical Devices Vigilance System [Note: attachment of the Guidelines is recommended]. DISTRIBUTOR will further
provide this technical support on the usage of products to the customers based on information supplied by MANUFACTURER. DISTRIBUTOR reporting should follow the current European Commission Guidelines On A Medical Devices Vigilance System. This
communication should occur within 10 days of DISTRIBUTOR becoming aware of an issue. If there is an issue with a TransEnterix product, pictures should be taken of the product for documentation purposes (if it is returned from the institution), and
then the product should be destroyed. 
 Emergo Europe 

Molenstraat 15 
 2513 BH The Hague

 The Netherlands 
 Tel:
(31) (0) 70 345-8570 
 Fax: (31) (0) 70 346-7299 

10). Product Recalls and Field Corrective Actions – DISTRIBUTOR shall report all customer complaints to TransEnterix. In the event
(i) any government authority issues a directive or order that a Product be recalled, (ii) a court of competent jurisdiction orders such a recall, or (iii) TransEnterix determines that a Product should be recalled or that a Field
Corrective Action should occur, the parties shall take all appropriate corrective actions. DISTRIBUTOR will, upon approval by TransEnterix, provide notice to customers of the recall of the Product. TransEnterix shall be responsible for the cost of
notifying end users and for determining the corrective actions to be taken and the reasonable costs associated with such actions, unless TransEnterix can affirmatively identify that the recall is a direct result of an act or omission of DISTRIBUTOR
or its agents or employees. TransEnterix and DISTRIBUTOR shall fully cooperate with one another and provide all reasonable assistance in conducting any recall or Field Corrective Action. DISTRIBUTOR shall maintain records of all sales of the
Products sufficient to carry out a recall with respect to Products purchased under the Agreement. The records shall be sufficient to recall specific product lot/serial numbers as identified on the external packaging of the product. 

11). Regulatory 
 a. Translations
– MANUFACTURER shall develop and include labeling translations with Products to customers in accordance with Territory requirements. 

b. Customer Complaints and Records Retention –A product complaint is any written or oral expression of dissatisfaction as to the identity,
quality, durability, reliability, safety, effectiveness, or performance of a Product. DISTRIBUTOR shall notify MANUFACTURER in writing within 5 business days of receipt of a product complaint. DISTRIBUTOR shall maintain records for 2 years from the
date a complaint is received. DISTRIBUTOR will provide initial 

  
 -2- 

 
problem troubleshooting to customers and then obtain an RMA, returned materials authorization, from MANUFACTURER as necessary. MANUFACTURER will maintain technical resources to enable it to
acknowledge reasonable requests from DISTRIBUTOR for responses to customer inquiries. 
 c. Re-packaging / Re-labeling - DISTRIBUTOR shall
not re-package or re-label any Product except as specifically authorized in writing by MANUFACTURER. MANUFACTURER authorizes DISTRIBUTOR to approves, additional labeling of the product using an inventory and shipping label similar to the one
attached in Annex 5. 
 d. Incidence Reporting – Product complaints associated with a death or serious injury, or a malfunction that
could reasonably be expected to result in a death or serious injury if the malfunction recurs are referred to as adverse incidents/adverse events and shall be reported by DISTRIBUTOR to MANUFACTURER immediately upon DISTRIBUTOR’S obtaining
knowledge thereof. In the event of any adverse incidents or adverse events involving the use of the Products, DISTRIBUTOR will promptly gather as much information regarding the incident as possible (including the name and contact information of the
doctor, the hospital, the patient, the date and the circumstances, the factors contributing to the incident, and any other information reasonably requested by MANUFACTURER) and report the matter to MANUFACTURER promptly upon becoming aware of the
incident as well as regulatory bodies as specified under the Medical Device Reporting regulations (21 CFR 803.24) and the European Union’s Medical Device Vigilance Guidelines and/or other applicable laws or regulations. DISTRIBUTOR shall
provide MANUFACTURER with a copy of any correspondence, reports, or other documents relating to such an incident promptly following receipt of such document by DISTRIBUTOR, and shall report to MANUFACTURER all available information concerning any
adverse usage experiences or product complaints of which it is aware in order to assist MANUFACTURER in monitoring the quality and safety of its Products, and to assist MANUFACTURER to meet its reporting obligations under the Medical Device
Reporting regulations (21 CFR 803.24) and the European Union’s Medical Device Vigilance Guidelines and/or other applicable laws or regulations. 

e. Shipping records/traceability – DISTRIBUTOR to maintain accurate and complete records of all sales of designated Products including lot
# / serial # by customer, quantities, date of sale, and shall provide them to MANUFACTURER (as requested by MANUFACTURER) to facilitate service actions/product notifications to customers as needed. 

f. Field Actions/Recalls – DISTRIBUTOR shall, upon approval by MANUFACTURER, provide notice to customers of field actions/recalls.
DISTRIBUTOR to maintain sales records sufficient to facilitate field actions. 
 g. HIPAA– DISTRIBUTOR and MANUFACTURER shall observe
HIPAA (U.S. Health Insurance Portability and Accountability Act) practices in as much as possible to safeguard sensitive data and protected health information. 

h. Territory Definition and Regulated Market Clearance/Approvals– the MANUFACTURER is responsible to assure that the Territory identified
in the contract is confirmed as a country that is currently cleared for marketing for the Product as identified in the contract. 

  
 -3- 

 i. Destination control - DISTRIBUTOR shall not sell outside Territory without prior written
consent of MANUFACTURER. 
 j. Regulatory Reporting – MANUFACTURER will inform DISTRIBUTOR without delay of new product risks and
incidents (adverse events) to protect patients and users in accordance with Articles 10 and 19 of the Medical device directive 93/42/EEC or other similarly described requirements from other applicable directives or regulations. 

k. Waste and Recycling – DISTRIBUTOR to comply with WEEE (in EU) or other applicable state/federal/national recycling requirements,
organize returned goods for recycling and waste take back. 
 l. List of Products and MDD Classification – a list of MANUFACTURER
products and MDD classification is provided in Annex 4. 
 12). Packaging & Labeling – DISTRIBUTOR will not re-package or
re-label without prior written agreement from TransEnterix. Should re-packaging/re-labeling be required, TransEnterix will provide DISTRIBUTOR with instructions. TransEnterix is aware of, and approves, relabeling of the product using a label similar
to the one attached in Annex 5. 
 13). Records – DISTRIBUTOR will retain all records related to complaints and shipped product for a
minimum of two (2) years. 
 14). Inventory – DISTRIBUTOR will insure that Products are handled and stored in an environment that
will maintain the quality, cleanliness, and proper functioning of the Products, according to product labeling and other communications provided by TransEnterix. 

15). Customer Service – DISTRIBUTOR will provide professional customer service support in territory. DISTRIBUTOR will take reasonable
measures to ensure that its customers are educated as to the proper use of the Products and that they understand the recommendations, precautions, contraindications and/or other notices shown on all package inserts and labeling. TransEnterix shall
advise DISTRIBUTOR staff as to the proper use of the Products, and provide such reasonable technical support and assistance to DISTRIBUTOR as DISTRIBUTOR may require to demonstrate the proper use of the Products to its customers. 

16). Advertising, Promotion and Trade Shows – All advertisements or other promotional materials pertaining to the Products proposed to be
used by DISTRIBUTOR shall be submitted to TransEnterix (Luke Roush) for approval prior to use or publication. 
 17). Term – This
agreement will end on 31st August 2012. Upon execution of this agreement, the Parties agree to negotiate in good faith to reach a formal distribution agreement for execution prior to 31 August 2012. If an agreement cannot be negotiated in
good faith by this end date, neither party is entitled to additional compensation, services, or rights in the future. 

  
 -4- 

 18). Jurisdiction – this agreement will be governed by North Carolina law. 

 

					
	TransEnterix, Inc.	 		  	Al Danah Medical Co. W.L.L.635
	Davis Drive, Suite 300	 		  	P.O. Box 14485
	Morrisville, NC 27560	 		  	Gate #4 Naser Bin Khaled Complex,
	USA	 		  	Salwa Road, Doha-Qatar
			
	 /s/ Luke Roush
	 		  	 /s/ Moh’d Afifi

	TransEnterix, Inc.	 		  	Al Danah Medical Co. W.L.L.
			
	Luke Roush	 		  	Moh’d Afifi General Manager
			
	VP of Sales and Global Marketing	 		  	General Manager

  
 -5- 

 Annex 1: 

Qatar and Kuwait 
 Annex 2: 

NOTE – discussed customers within Territory are OK, as long as written approval exists from TransEnterix. 

 Annex 3: 
  

 
  

 Annex 4:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]